即时 PCR、数位 PCR 和终点 PCR 市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按技术、产品、按应用、地区、竞争预测和机会细分，2018 年-2028F

2022 年，全球即时 PCR、数位 PCR 和端点 PCR 市场估值达到 80.1 亿美元，预计到 2028 年将以 6.03% 的复合年增长率 (CAGR) 成长。市场的特征是三种不同的技术：即时PCR 、数位PCR 和端点PCR。

实时 PCR 价值约 40 亿美元，是该市场的主导部分。它之所以能保持这一地位，是因为它在即时定量测量 DNA 扩增方面具有多功能性。即时 PCR 在临床诊断、基因表现分析和病原体检测方面有着广泛的应用，赛默飞世尔科技 (Thermo Fisher Scientific) 和 Bio-Rad Laboratories 等行业领导者引领市场。

数位PCR虽然规模较小，市场价值约4.5亿美元，但正在快速成长。这种增长归因于其核酸定量的精确性及其在罕见突变检测中的应用。

市场概况
预测期	2024-2028
2022 年市场规模	80.1亿美元
2028 年市场规模	114.7亿美元
2023-2028 年复合年增长率	6.03%
成长最快的细分市场	临床
最大的市场	北美洲

端点 PCR 是一项具有稳定市场规模的成熟技术，对于各种分子生物学应用（包括基因分型、DNA 定序和传染病诊断）仍然至关重要。

主要市场驱动因素

慢性病、传染病和遗传性疾病的发生率上升

慢性病、传染病和遗传性疾病的发生率不断上升，大大推动了即时 PCR、数位 PCR 和端点 PCR 市场的发展。癌症、心血管疾病和糖尿病等慢性疾病的全球负担正在上升。这些疾病需要早期发现和精确监测。即时 PCR 具有即时定量功能，可及时识别与这些病症相关的遗传标记。数位 PCR 以其无与伦比的精确度而闻名，有助于检测罕见突变，促进早期干预和个人化治疗策略。传染病（包括最近的流行病）的出现强调了准确诊断的必要性。即时 PCR 在检测病毒、细菌和真菌病原体方面发挥了重要作用。其速度和灵敏度支持快速识别和遏制传染源。同时，数位 PCR 提高了病毒量监测的灵敏度，这对于控制传染病至关重要。

遗传性疾病需要彻底了解个体的遗传特征。即时和数位 PCR 在基因检测中至关重要，能够检测与遗传性疾病相关的基因突变。这有助于早期诊断、客製化治疗和遗传咨询。因此，这些疾病的激增需要先进的诊断工具。即时 PCR、数位 PCR 和终点 PCR 以其精确度和灵敏度，对于应对这些医疗挑战、实现更早检测、更有针对性的治疗和改善患者治疗效果是不可或缺的。

快速诊断测试的需求不断增加，Qpcr 和 Dpcr 的采用不断增加

由于两个关键因素，实时 PCR、数位 PCR 和端点 PCR 市场的需求大幅增长：对快速诊断测试的需求不断增加，以及 qPCR（定量 PCR）和 dPCR（数位 PCR）技术的日益采用。由于需要及时检测和监测疾病，特别是在传染病方面，对快速、准确的诊断测试的需求不断升级。即时 PCR 能够提供快速、精确的结果，已成为诊断的基石。它使医疗保健专业人员能够快速识别病原体，这使得它在像 COVID-19 大流行这样的情况下具有无价的价值。

定量 PCR (qPCR) 和数位 PCR (dPCR) 因其无与伦比的精度和灵敏度而在研究和临床环境中获得了广泛关注。研究人员越来越依赖这些技术来准确定量核酸。在诊断领域，dPCR 凭藉其绝对定量能力，被证明是一种游戏规则改变者，特别是在监测传染病的病毒载量方面。快速诊断的需求以及 qPCR 和 dPCR 技术的采用推动了诊断技术的发展即时PCR、数位PCR 和端点PCR 市场。这些技术不仅满足了快速、准确检测的需求，而且还能够实现更早的疾病检测、量身定制的治疗和改善患者的治疗结果。随着医疗保健的不断发展，这些 PCR 技术将在塑造诊断和研究的未来方面发挥关键作用。

实施 MIQE（定量即时 PCR 实验发布的最低资讯）

MIQE（定量即时 PCR 实验发布的最低限度资讯）指南的实施对即时 PCR、数位 PCR 和终点 PCR 市场产生了重大影响。这些指南为进行和报告定量 PCR 实验提供了标准化框架，提高了资料的准确性、可重复性和可靠性。以下是 MIQE 推动 PCR 市场的方式：符合 MIQE 的研究遵循严格的实验设计和报告标准，确保 PCR 产生资料的准确性和完整性。研究人员和临床医生在工作中越来越重视高品质资料，刺激了对先进 PCR 技术的需求。遵守 MIQE 可提高基于 PCR 的研究的可信度，促进科学界的更大信任。这带来了更多的合作研究，加快了科学发现的步伐，推动了即时 PCR、数位 PCR 和端点 PCR 技术的采用。在临床诊断中，MIQE 合规性对于确保患者测试结果的准确性至关重要。监管机构和医疗机构越来越多地要求基于 PCR 的诊断测定遵守 MIQE，从而推动了 PCR 仪器和试剂的使用。 MIQE 指南制定的严格标准需要高品质的 PCR 仪器、试剂和软体。这推动了对尖端 PCR 技术的投资，扩大了这些 PCR 解决方案的市场。

因此，MIQE指南的实施已成为PCR市场成长的催化剂。研究人员、临床医生和监管机构越来越认识到 MIQE 合规性的重要性，推动即时 PCR、数位 PCR 和终点 PCR 技术在广泛的科学和临床应用中的采用。

PCR（聚合酶炼式反应）的技术进步

PCR（聚合酶炼式反应）的技术进步正在推动即时 PCR、数位 PCR 和端点 PCR 市场进入精确、高效和多功能的新时代。这些进步正在推动 PCR 技术在各个行业和应用中的采用。持续的研究和开发努力使得 PCR 系统具有更高的灵敏度和精确度。特别是即时 PCR 和数位 PCR 现在可以以前所未有的精度检测和定量核酸，彻底改变基因组学研究、临床诊断和个人化医疗。 PCR 技术已经发展到能够进行多重检测，因此可以在一次反应中同时分析多个遗传标靶。这不仅节省了时间，也节省了资源。高通量PCR系统的出现，满足了快速、大规模检测的需求，特别是在临床诊断和药物发现方面。

PCR 仪器越来越多地与自动化系统集成，简化了实验室工作流程并最大限度地减少人为错误。这在可靠性和速度至关重要的临床环境中至关重要。小型化和便携性使得护理点 PCR 设备可以部署在偏远或资源有限的地区。这些紧凑型系统正在扩大 PCR 在传染病诊断和监测中的应用。 PCR 已成为 NGS 工作流程的一个组成部分，有助于在定序前进行标靶扩增。这种整合加速了基因组学和分子生物学研究的进步。因此，技术突破正在重塑 PCR 格局，推动即时 PCR、数位 PCR 和端点 PCR 在不同领域的采用。这些创新扩大了 PCR 的应用范围，使其成为现代科学、医学和诊断中不可或缺的工具。

主要市场挑战

与实时 PCR 相关的高设备成本

与即时 PCR 相关的高设备成本已成为即时 PCR、数位 PCR 和端点 PCR 市场的重大挑战。虽然这些技术提供了无与伦比的精度和灵敏度，但它们的初始投资和持续营运费用可能相当大，造成了一些障碍：购买即时PCR、数位PCR 或终点PCR 仪器的巨额前期成本可能会阻碍小型研究实验室、诊所、和资源有限的地区采用这些技术。这限制了他们获得先进的分子诊断能力。除了最初购买之外，PCR 仪器还需要定期维护和使用专用耗材，例如试剂和一次性用品。这些持续的支出可能会导致预算紧张，特别是在财务紧张的医疗保健环境中。正确使用 PCR 系统需要经过训练并具有分子生物学技术专业知识的人员。对员工培训的投资增加了实施和维护 PCR 技术的整体成本。

与其他一些诊断方法相比，基于 PCR 的检测的每次测试成本可能更高。这可能是医疗保健提供者和患者所关心的问题，可能会限制这些技术的广泛采用。 PCR 仪器的高成本导致市场竞争激烈，製造商努力提供具有成本效益的解决方案。虽然这对消费者有利，但它可能对製造商维持获利能力构成挑战。因此，虽然即时 PCR、数位 PCR 和终点 PCR 提供卓越的诊断能力，但其高昂的设备成本提出了重大挑战。为了克服这一障碍并促进更广泛的采用，该行业必须继续探索具有成本效益的创新，简化营运费用，并促进在不同的医疗保健和研究环境中使用这些先进的分子诊断技术。

严格的监理政策

严格的监管政策为即时 PCR、数位 PCR 和端点 PCR 市场带来了巨大的挑战。虽然法规对于确保诊断设备的安全性和可靠性至关重要，但它们通常会为产业的成长和创新带来一些障碍。主要挑战之一在于获得监管批准的漫长且耗费资源的过程。公司必须完成复杂且耗时的程序，例如美国的 FDA 许可或欧洲的 CE 标誌。这些核准延迟可能会严重阻碍新的 PCR 技术推向市场。合规成本是另一个主要问题。满足严格的监管要求需要在测试、文件和品质控制措施方面进行大量投资。这些费用可能会增加 PCR 技术的整体成本，这可能使医疗保健提供者和患者更难获得这些技术。严格的监管环境也会阻止规模较小的创新公司进入市场。遵守复杂的法规可能需要大量的财力和人力资源，这限制了新型 PCR 技术的发展。

此外，不同地区往往有自己的监管框架，导致差异和不一致。对于想要在全球销售其产品的製造商来说，遵守各种规则可能会很麻烦。因此，虽然监管政策对于确保患者安全和产品品质至关重要，但它们也为即时 PCR、数位 PCR 和端点 PCR 市场带来了重大挑战。在严格的法规与创新和市场准入之间取得平衡对于推动行业发展并为医疗保健提供者和患者提供先进的诊断工具至关重要。

主要市场趋势

基因组学研究

基因组学研究在推动即时 PCR、数位 PCR 和端点 PCR 市场的成长方面发挥关键作用。该研究领域专注于了解生物体的完整基因（其基因组），在很大程度上依赖聚合酶炼式反应 (PCR) 技术来实现多种应用。

主要驱动因素之一是 DNA 扩增和定序的需求，这是基因组学研究的基本过程。 PCR 技术使研究人员能够选择性地扩增特定 DNA 区域，从而促进遗传变异、突变和基因表现模式的分析。此外，新一代定序（NGS）的出现进一步凸显了PCR的重要性。 NGS 在定序前依靠 PCR 进行目标扩增，这使得 PCR 成为基因组学工作流程中的关键组成部分。 PCR 和 NGS 之间的这种协同作用将基因组学研究推向了新的维度，使研究人员能够探索复杂的生物学问题并揭示基因组见解。

此外，基因组学研究在个人化医疗、农业和演化生物学等领域具有深远的影响。随着基因组学研究范围的扩大，对准确、高通量和经济高效的 PCR 技术的需求激增。因此，基因组学研究对 DNA 分析和测序的永不满足的需求刺激了对即时 PCR、数位 PCR 和终点 PCR 技术的需求。这些 PCR 技术是基因组学研究人员工具包中不可或缺的工具，为我们对遗传学的理解做出了重大贡献，并推动了科学、医学等领域的创新。

即时检测 (POCT)

即时 PCR 检测 (POCT) 已成为即时 PCR、数位 PCR 和端点 PCR 市场的显着趋势，改变了诊断和医疗保健实践的模式。这种转变是由几个关键因素所驱动的。对快速、现场诊断的需求从未如此迫切，特别是在传染病爆发等情况下，快速、准确的结果可能事关生死。 PCR 技术，包括即时 PCR 和数位 PCR，已发展以满足这一需求。便携式紧凑型 PCR 设备现已上市，使医疗保健专业人员能够在患者床边或远端位置进行分子诊断。其次，COVID-19 大流行凸显了使用 PCR 技术进行 POCT 的重要性。尤其是即时 PCR 在大规模检测工作中发挥了核心作用，强调了该技术对快速和广泛诊断的适应性。此外，检测设施的分散化是医疗保健领域的一个日益增长的趋势。 POCT 减少了将样本送到集中实验室的需要，从而节省了时间和资源。这种权力下放也促进了早期诊断和治疗，改善了患者的治疗效果。此外，随着 PCR 设备变得更加用户友好且需要更少的技术专业知识，它们在 POCT 环境中的采用对于传统实验室之外的医疗保健提供者来说变得更加可行。总体而言，使用 PCR 技术进行即时检测的趋势是由对快速、准确和易于访问的诊断的需求所推动的。随着这些技术的不断发展，它们预计将在医疗保健领域发挥越来越重要的作用，提供及时的见解并改善患者护理。

细分市场洞察

产品洞察

耗材和试剂领域成为主要的收入贡献者，到 2022 年在实时 PCR、数位 PCR 和端点 PCR 市场中占据超过 56.51% 的巨大份额。这种主导地位可归因于塑造其成长轨迹的几个关键因素。 COVID-19 大流行的爆发对诊断检测产生了前所未有的需求，其中 PCR 技术发挥了关键作用。耗材和试剂是PCR检测的基本组成部分，检测需求的激增大大增加了耗材和试剂的消耗。大流行期间对早期和准确疾病检测的需求进一步刺激了需求。其次，从事数位PCR耗材和试剂製造的公司众多，也促成了该领域的突出地位。该领域的竞争导致了产品创新和更广泛的产品，以满足不同的研究和诊断需求。

此外，消耗品和试剂在医疗保健、研究和其他科学应用等各个领域的广泛使用，维持了该细分市场的巨大市场份额。这些耗材是常规实验室实践不可或缺的一部分，可确保研究和诊断的连续性。此外，慢性病盛行率的上升导致PCR技术的使用增加，增加了对耗材和试剂的需求。此外，製药和医疗保健行业对技术进步的日益接受以及研发活动的增加，将在可预见的未来为该领域创造巨大的成长机会。总之，耗材和试剂领域在即时PCR、数位PCR 和端点PCR 市场中的主导地位是多种因素综合作用的结果，包括COVID-19 大流行、竞争性的製造环境、广泛的应用以及不断变化的趋势。扩大研究和医疗保健领域。随着市场的不断发展，这种主导地位将持续存在。

技术洞察

定量PCR细分市场确立了其市场主导地位，到2022年占据了超过88.63%的可观收入份额。多种驱动力将该细分市场推向最前沿，塑造了其显着的成长轨迹。首先，科技进步的快速发展是定量PCR领域崛起的催化剂。这些进步导致了更复杂和用户友好的 PCR 系统的开发，满足研究人员和诊断人员不断变化的需求。其次，对自动化 PCR 系统和即时诊断的需求不断增长。自动化系统提供的便利性和效率引起了人们的极大兴趣，进一步推动了定量 PCR 领域的成长。此外，由于全球对 COVID-19 大流行的反应，该细分市场的需求呈指数级增长。用于 COVID-19 筛检和诊断的基于实时 PCR 的产品的推出在这一增长中发挥了关键作用。例如，Huwel Lifesciences 于 2023 年 2 月推出了一款便携式 RT-PCR 机器，旨在测试各种病毒类型，提高了测试的可及性。

此外，布鲁克公司于 2020 年 3 月宣布的 genesig 即时 PCR 冠状病毒检测分销协议等分销协议促进了定量 PCR 技术的广泛采用。这些协议扩大了美国、英国、西班牙、法国和德国等地区关键诊断工具的可用性。总之，定量 PCR 领域在市场上的优势可归因于多种因素的综合作用，包括技术创新、对自动化和即时诊断的需求增加，以及它在 COVID-19 检测中发挥的关键作用。该细分市场预计将在可预见的未来保持强劲的成长轨迹。

区域洞察

2022年，北美在全球市场舞台上占据领先地位，营收份额超过36.10%。这种强势地位预计将在整个预测期内持续存在，有几个关键因素导致了这种持续的主导地位。主要驱动因素之一是旨在推进医疗基础设施的有利法规和政府主导的倡议的存在。北美透过支持性监管框架积极促进包括 PCR 诊断在内的医疗保健技术的发展。此外，该地区还面临疾病高发生率的问题，因此需要可靠、高效的诊断解决方案。

此外，北美拥有众多领先的 PCR 技术製造商，进一步巩固了其作为该领域创新和生产中心的地位。这种本土专业知识确保该地区能够满足快速、精确诊断测试不断增长的需求。将重点转移到亚太地区，该地区成为最有前途和最有利可图的市场。中国和日本在将 PCR 技术融入各种应用方面取得了显着进展。此外，印度和澳洲等新兴经济体正在积极发展其医疗保健、研究和临床框架，为该地区的成长潜力做出贡献。

总体而言，北美的主导地位归因于监管支持、政府倡议和疾病流行，而亚太地区则因技术整合以及不断扩大的医疗保健和研究领域而表现出色。这些因素使这两个地区的 PCR 市场在可预见的未来都将大幅成长。

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球即时 PCR、数位 PCR 和终点 PCR 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按技术（定量、数字、端点）
  • 按产品（消耗品和试剂、仪器、软体和服务）
  • 按应用（临床、研究）
  • 按公司划分 (2022)
  • 按地区
• 市场地图

第 6 章：北美即时 PCR、数位 PCR 和终点 PCR 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按产品分类
  • 按应用
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 7 章：欧洲即时 PCR、数位 PCR 和终点 PCR 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按产品分类
  • 按应用
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区即时 PCR、数位 PCR 和终点 PCR 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按产品分类
  • 按应用
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲即时 PCR、数位 PCR 和终点 PCR 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按产品分类
  • 按应用
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲即时 PCR、数位 PCR 和终点 PCR 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按类型
  • 依给药途径
  • 按国家/地区
• MEA：国家分析
  • 南非 即时 PCR、数位 PCR 和终点 PCR
  • 沙乌地阿拉伯 实时 PCR、数位 PCR 和终点 PCR
  • 阿联酋即时 PCR、数位 PCR 和终点 PCR

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• 商业概览
• 公司概况
• 产品与服务
• 财务（上市公司）
• 最近的发展
• SWOT分析
  • Abbott Laboratories Inc
  • Bio-Rad Laboratories Inc.
  • Thermo Fisher Scientific, Inc.
  • BIOMERIEUX SA
  • Fluidigm Corporation
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Agilent Technologies, Inc.
  • Qiagen NV
  • Microsynth Ag

第 16 章：策略建议

In 2022, the Global Real-time PCR, Digital PCR & Endpoint PCR Market reached a valuation of USD 8.01 billion and is projected to grow with a Compound Annual Growth Rate (CAGR) of 6.03% by 2028. This PCR (Polymerase Chain Reaction) market is characterized by three distinct techniques: Real-time PCR, Digital PCR, and Endpoint PCR.

Real-time PCR, valued at approximately USD 4 billion, stands as the dominant segment within this market. It holds this position due to its versatility in quantitatively measuring DNA amplification in real-time. Real-time PCR finds extensive applications in clinical diagnostics, gene expression analysis, and pathogen detection, with industry leaders such as Thermo Fisher Scientific and Bio-Rad Laboratories leading the market.

Digital PCR, although smaller in size with a market value of around USD 450 million, is experiencing rapid growth. This growth is attributed to its precision in nucleic acid quantification and its applications in the detection of rare mutations.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 8.01 Billion
Market Size 2028	USD 11.47 Billion
CAGR 2023-2028	6.03%
Fastest Growing Segment	Clinical
Largest Market	North America

Endpoint PCR, a mature technology with a stable market size, remains crucial for various molecular biology applications, including genotyping, DNA sequencing, and infectious disease diagnostics.

All three PCR techniques are continuously evolving through technological advancements and are witnessing increased demand in healthcare and life sciences. They cater to specific research and diagnostic needs, thereby contributing to the market's growth and diversification.

Key Market Drivers

Rising Incidence Of Chronic Diseases, Infectious Diseases, And Genetic Disorders

The escalating incidence of chronic diseases, infectious diseases, and genetic disorders is significantly propelling the Real-time PCR, Digital PCR, and Endpoint PCR market. The global burden of chronic illnesses such as cancer, cardiovascular diseases, and diabetes is on the rise. These diseases necessitate early detection and precise monitoring. Real-time PCR, with its real-time quantitative capabilities, allows for the timely identification of genetic markers associated with these conditions. Digital PCR, known for its unparalleled precision, aids in detecting rare mutations, facilitating early intervention and personalized treatment strategies. The emergence of infectious diseases, including recent pandemics, emphasizes the need for accurate diagnostics. Real-time PCR has been instrumental in detecting viral, bacterial, and fungal pathogens. Its speed and sensitivity support swift identification and containment of infectious agents. Meanwhile, Digital PCR offers enhanced sensitivity for monitoring viral load, critical for managing infectious diseases.

Genetic disorders demand a thorough understanding of an individual's genetic profile. Real-time and Digital PCR are pivotal in genetic testing, enabling the detection of genetic mutations linked to inherited disorders. This assists in early diagnosis, tailored treatment, and genetic counseling. Therefore, the surge in these diseases necessitates advanced diagnostic tools. Real-time PCR, Digital PCR, and Endpoint PCR, with their precision and sensitivity, are indispensable in addressing these healthcare challenges, leading to earlier detection, more targeted treatments, and improved patient outcomes.

Increasing Demand For Rapid Diagnostic Tests And Growing Adoption Of Qpcr & Dpcr

The Real-time PCR, Digital PCR, and Endpoint PCR market are witnessing a significant surge in demand due to two key factors: the increasing need for rapid diagnostic tests and the growing adoption of qPCR (quantitative PCR) and dPCR (digital PCR) technologies. The demand for quick and accurate diagnostic tests is escalating, driven by the need for timely disease detection and monitoring, particularly in the context of infectious diseases. Real-time PCR, with its ability to deliver rapid and precise results, has become a cornerstone in diagnostics. It enables healthcare professionals to swiftly identify pathogens, making it invaluable in situations like the COVID-19 pandemic.

Quantitative PCR (qPCR) and digital PCR (dPCR) have gained traction in both research and clinical settings due to their unmatched precision and sensitivity. Researchers are increasingly relying on these techniques to quantify nucleic acids accurately. In diagnostics, dPCR, with its absolute quantification capabilities, is proving to be a game-changer, especially in monitoring viral loads in infectious diseases.The convergence of the need for rapid diagnostics and the adoption of qPCR and dPCR technologies has fueled the growth of the Real-time PCR, Digital PCR, and Endpoint PCR market. These techniques are not only meeting the demand for rapid and accurate testing but are also enabling earlier disease detection, tailored treatments, and improved patient outcomes. As healthcare continues to evolve, these PCR technologies are poised to play pivotal roles in shaping the future of diagnostics and research.

implementation of MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments)

The implementation of MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines is exerting a significant influence on the Real-time PCR, Digital PCR, and Endpoint PCR market. These guidelines provide a standardized framework for conducting and reporting quantitative PCR experiments, promoting data accuracy, reproducibility, and reliability. Here's how MIQE is driving the PCR market: MIQE-compliant studies adhere to stringent experimental design and reporting standards, ensuring the accuracy and integrity of PCR-generated data. Researchers and clinicians increasingly prioritize high-quality data in their work, spurring the demand for advanced PCR technologies. MIQE adherence enhances the credibility of PCR-based research, facilitating greater trust in the scientific community. This leads to more collaborative studies and accelerates the pace of scientific discovery, driving the adoption of Real-time PCR, Digital PCR, and Endpoint PCR technologies. In clinical diagnostics, MIQE compliance is critical to guarantee the precision of patient test results. Regulatory bodies and healthcare institutions are increasingly requiring MIQE adherence for PCR-based diagnostic assays, propelling the use of PCR instruments and reagents. The strict standards set by MIQE guidelines necessitate high-quality PCR instruments, reagents, and software. This drives investments in cutting-edge PCR technology, expanding the market for these PCR solutions.

Therefore implementation of MIQE guidelines has become a catalyst for the PCR market's growth. Researchers, clinicians, and regulatory bodies increasingly recognize the significance of MIQE compliance, promoting the adoption of Real-time PCR, Digital PCR, and Endpoint PCR technologies across a wide range of scientific and clinical applications.

Technological advancements in PCR (Polymerase Chain Reaction)

Technological advancements in PCR (Polymerase Chain Reaction) are propelling the Real-time PCR, Digital PCR, and Endpoint PCR market into a new era of precision, efficiency, and versatility. These advancements are driving the adoption of PCR techniques across various industries and applications. Continuous research and development efforts have led to PCR systems with greater sensitivity and precision. Real-time PCR and Digital PCR, in particular, can now detect and quantify nucleic acids with unprecedented accuracy, revolutionizing genomics research, clinical diagnostics, and personalized medicine. PCR techniques have evolved to enable multiplexing, allowing the simultaneous analysis of multiple genetic targets in a single reaction. This not only saves time but also conserves resources. High-throughput PCR systems have emerged, meeting the demand for rapid and large-scale testing, especially in clinical diagnostics and drug discovery.

PCR instruments are increasingly being integrated with automation systems, streamlining laboratory workflows and minimizing human error. This is vital in clinical settings where reliability and speed are paramount. Miniaturization and portability have resulted in point-of-care PCR devices that can be deployed in remote or resource-limited areas. These compact systems are expanding the use of PCR in infectious disease diagnosis and monitoring. PCR has become an integral component of NGS workflows, facilitating target amplification before sequencing. This integration has accelerated advancements in genomics and molecular biology research. Therefore, technological breakthroughs are reshaping the PCR landscape, fueling the adoption of Real-time PCR, Digital PCR, and Endpoint PCR across diverse sectors. These innovations are broadening the scope of PCR applications, making it an indispensable tool in modern science, medicine, and diagnostics.

Key Market Challenges

High Device Costs Associated With Real Time Pcr

The high device costs associated with Real-time PCR have become a significant challenge for the Real-time PCR, Digital PCR, and Endpoint PCR market. While these technologies offer unparalleled precision and sensitivity, their initial investment and ongoing operational expenses can be substantial, creating several hurdles: The considerable upfront cost of purchasing Real-time PCR, Digital PCR, or Endpoint PCR instruments can deter smaller research laboratories, clinics, and resource-constrained regions from adopting these technologies. This limits their access to advanced molecular diagnostic capabilities. Beyond the initial purchase, PCR instruments require regular maintenance and the use of specialized consumables, such as reagents and disposables. These ongoing expenses can strain budgets, particularly in healthcare settings with tight financial constraints. Proper utilization of PCR systems demands trained personnel with expertise in molecular biology techniques. Investing in staff training adds to the overall cost of implementing and maintaining PCR technologies.

The cost per test with PCR-based assays can be higher compared to some other diagnostic methods. This can be a concern for healthcare providers and patients, potentially limiting the widespread adoption of these techniques. The high cost of PCR instruments has led to a competitive market, with manufacturers striving to offer cost-effective solutions. While this benefits consumers, it can pose a challenge for manufacturers in terms of maintaining profitability. Therefore, while Real-time PCR, Digital PCR, and Endpoint PCR offer exceptional diagnostic capabilities, their high device costs present a significant challenge. To overcome this obstacle and promote broader adoption, the industry must continue to explore cost-effective innovations, streamline operational expenses, and facilitate accessibility to these advanced molecular diagnostic technologies across diverse healthcare and research settings.

Stringent Regulatory Policies

Stringent regulatory policies present a considerable challenge for the Real-time PCR, Digital PCR, and Endpoint PCR market. While regulations are essential for ensuring the safety and reliability of diagnostic devices, they often pose several hurdles to the industry's growth and innovation. One of the primary challenges lies in the lengthy and resource-intensive process of obtaining regulatory approvals. Companies must navigate complex and time-consuming procedures, such as FDA clearance in the United States or CE marking in Europe. These approval delays can significantly impede the introduction of new PCR technologies to the market. Compliance costs are another major concern. Meeting stringent regulatory requirements demands substantial investments in testing, documentation, and quality control measures. These expenses can increase the overall cost of PCR technologies, potentially making them less accessible to healthcare providers and patients. The stringent regulatory landscape can also deter smaller, innovative companies from entering the market. Compliance with complex regulations may require significant financial and human resources, limiting the development of novel PCR technologies.

Moreover, different regions often have their own regulatory frameworks, resulting in variations and inconsistencies. Adhering to various sets of rules can be burdensome for manufacturers aiming to market their products globally. Therefore, while regulatory policies are crucial for ensuring patient safety and product quality, they create significant challenges for the Real-time PCR, Digital PCR, and Endpoint PCR market. Balancing stringent regulations with innovation and market access is essential to drive the industry forward and provide healthcare providers and patients with advanced diagnostic tools.

Key Market Trends

Genomics research

Genomics research is playing a pivotal role in driving the growth of the Real-time PCR, Digital PCR, and Endpoint PCR market. This field of study, focused on understanding the complete set of an organism's genes (its genome), relies heavily on Polymerase Chain Reaction (PCR) technologies for a multitude of applications.

One of the primary drivers is the need for DNA amplification and sequencing, which are fundamental processes in genomics research. PCR techniques enable researchers to selectively amplify specific DNA regions, facilitating the analysis of genetic variations, mutations, and gene expression patterns. Moreover, the emergence of next-generation sequencing (NGS) has further accentuated the importance of PCR. NGS relies on PCR for target amplification before sequencing, making PCR a critical component in the genomics workflow. This synergy between PCR and NGS has propelled genomics research into new dimensions, enabling researchers to explore complex biological questions and uncover genomic insights.

Additionally, genomics research has far-reaching implications in fields such as personalized medicine, agriculture, and evolutionary biology. The demand for accurate, high-throughput, and cost-effective PCR technologies has surged as genomics research expands its horizons. Therefore, genomics research's insatiable appetite for DNA analysis and sequencing has fueled the demand for Real-time PCR, Digital PCR, and Endpoint PCR technologies. These PCR techniques are indispensable tools in the genomics researcher's toolkit, contributing significantly to our understanding of genetics and driving innovations in science, medicine, and beyond.

Point-of-care testing (POCT)

Point-of-care testing (POCT) has emerged as a prominent trend in the Real-time PCR, Digital PCR, and Endpoint PCR market, transforming the landscape of diagnostic and healthcare practices. This shift is driven by several key factors. The need for rapid and on-the-spot diagnostics has never been more critical, particularly in scenarios like infectious disease outbreaks, where quick and accurate results can be a matter of life and death. PCR technologies, including Real-time PCR and Digital PCR, have evolved to meet this demand. Portable and compact PCR devices are now available, allowing healthcare professionals to perform molecular diagnostics at the patient's bedside or in remote locations. Secondly, the COVID-19 pandemic highlighted the significance of POCT using PCR techniques. Real-time PCR, in particular, played a central role in mass testing efforts, emphasizing the technology's adaptability for rapid and widespread diagnostics. Furthermore, the decentralization of testing facilities is a growing trend in healthcare. POCT reduces the need for sending samples to centralized laboratories, saving time and resources. This decentralization also promotes early diagnosis and treatment, improving patient outcomes. In addition, as PCR devices become more user-friendly and require less technical expertise, their adoption in POCT settings becomes more feasible for healthcare providers beyond traditional laboratories. Overall, the trend towards point-of-care testing using PCR technologies is driven by the demand for quick, accurate, and accessible diagnostics. As these technologies continue to evolve, they are expected to play an increasingly significant role in healthcare, offering timely insights and improving patient care.

Segmental Insights

Product Insights

The consumables and reagents segment emerged as the dominant revenue contributor, accounting for a substantial share of over 56.51% in 2022 within the Real-time PCR, Digital PCR, and Endpoint PCR market. This dominance can be attributed to several key factors that have shaped its growth trajectory. The outbreak of the COVID-19 pandemic created an unprecedented demand for diagnostic testing, where PCR technologies played a pivotal role. Consumables and reagents are fundamental components of PCR assays, and the surge in testing requirements significantly boosted their consumption. The need for early and accurate disease detection during the pandemic further fueled demand. Secondly, the multitude of companies engaged in the manufacturing of digital PCR consumables and reagents contributed to the segment's prominence. Competition in this sector led to product innovation and a wider range of offerings, catering to diverse research and diagnostic needs.

Moreover, the extensive use of consumables and reagents across various domains, including healthcare, research, and other scientific applications, has sustained the segment's large market share. These consumables are integral to routine laboratory practices, ensuring the continuity of research and diagnostics. Furthermore, the rising prevalence of chronic diseases has led to increased utilization of PCR technologies, consequently bolstering the demand for consumables and reagents. Additionally, the pharmaceutical and healthcare sectors' growing acceptance of technological advancements and increased research and development activities are set to create significant growth opportunities for this segment in the foreseeable future. In conclusion, the consumables and reagents segment's dominance in the Real-time PCR, Digital PCR, and Endpoint PCR market is the result of a confluence of factors, including the COVID-19 pandemic, competitive manufacturing landscape, widespread application, and the ever-expanding realm of research and healthcare. This dominance is poised to persist as the market continues to evolve.

Technology Insights

The quantitative PCR segment established its dominance in the market, capturing a substantial revenue share of over 88.63% in 2022. Several driving forces have propelled this segment to the forefront, shaping its remarkable growth trajectory. Firstly, the rapid pace of technological advancements has been a catalyst for the quantitative PCR segment's ascent. These advancements have led to the development of more sophisticated and user-friendly PCR systems, catering to the evolving needs of researchers and diagnosticians. Secondly, there is a growing demand for automated PCR systems and point-of-care diagnostics. The convenience and efficiency offered by automated systems have garnered significant interest, further propelling the quantitative PCR segment's growth. Additionally, the segment has experienced an exponential surge in demand due to the global response to the COVID-19 pandemic. The introduction of real-time PCR-based products for COVID-19 screening and diagnosis has played a pivotal role in this growth. For example, Huwel Lifesciences unveiled a portable RT-PCR machine in February 2023 designed to test various virus types, enhancing accessibility to testing.

Furthermore, distribution agreements, such as the one announced by Bruker Corporation in March 2020 for the distribution of genesig real-time PCR coronavirus assay, have facilitated the widespread adoption of quantitative PCR technologies. These agreements have expanded the availability of critical diagnostic tools in regions including the U.S., the U.K., Spain, France, and Germany. In conclusion, the quantitative PCR segment's ascendancy in the market can be attributed to a confluence of factors, including technological innovations, increased demand for automation and point-of-care diagnostics, and the pivotal role it has played in COVID-19 testing. This segment is poised to maintain its strong growth trajectory in the foreseeable future.

Regional Insights

In 2022, North America took the lead on the global market stage, capturing a significant revenue share of over 36.10%. This strong position is expected to persist throughout the forecast period, and several key factors are responsible for this continued dominance. One of the primary drivers is the presence of favorable regulations and government-led initiatives aimed at advancing healthcare infrastructure. North America has actively promoted the development of healthcare technologies, including PCR diagnostics, through supportive regulatory frameworks. Additionally, the region grapples with a high prevalence of diseases, necessitating reliable and efficient diagnostic solutions.

Moreover, North America boasts a robust presence of leading PCR technology manufacturers, further cementing its status as a hub for innovation and production in this sector. This homegrown expertise ensures that the region can meet the escalating demand for rapid and precise diagnostic tests. Shifting the focus to Asia Pacific, this region emerges as the most promising and lucrative market. China and Japan stand out for their notable advancements in integrating PCR technology into various applications. Furthermore, emerging economies like India and Australia are actively developing their healthcare, research, and clinical frameworks, contributing to the region's growth potential.

Overall, North America's dominance is attributed to regulatory support, government initiatives, and disease prevalence, while the Asia Pacific region shines with technological integration and expanding healthcare and research sectors. These factors position both regions for substantial growth in the PCR market in the foreseeable future.

Key Market Players

• Abbott Laboratories Inc

• Bio-Rad Laboratories Inc.

• Thermo Fisher Scientific, Inc.

• BIOMERIEUX SA

• Fluidigm Corporation

• F. Hoffmann-La Roche Ltd

• GE Healthcare

• Agilent Technologies, Inc.

• Qiagen NV

• Microsynth Ag

Report Scope:

In this report, the Global Real-time PCR, Digital PCR & End-point PCR Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Real-time PCR, Digital PCR & End-point PCR Market, By Technology:

• Quantitative
• Digital
• Endpoint

Real-time PCR, Digital PCR & End-point PCR Market, By Product:

• Consumables & Reagents
• Instruments
• Software & Services

Real-time PCR, Digital PCR & End-point PCR Market, By Application:

• Clinical
• Research

Real-time PCR, Digital PCR & End-point PCR Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Real-time PCR, Digital PCR & End-point PCR Market.

Available Customizations:

• Global Real-time PCR, Digital PCR & End-point PCR market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customers

5. Global Real-time PCR, Digital PCR & End-point PCR Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Quantitative, Digital, Endpoint)
    • 5.2.1.1. By Quantitative (Consumables & Reagents, Instruments, Software & Services)
    • 5.2.1.2. By Digital (Consumables & Reagents, Instruments, Software & Services)
    • 5.2.1.3. By Endpoint (Consumables & Reagents, Instruments, Software & Services)
  • 5.2.2. By Product (Consumables & Reagents, Instruments, Software & Services)
  • 5.2.3. By Application (Clinical, Research)
    • 5.2.3.1. By Clinical (Pathogen Testing, Oncology Testing, Blood Screening, Liquid Biopsy Testing, Dpcr-Based Non-Invasive Prenatal Testing)
    • 5.2.3.2. By Research (Stem Cell Research, Dna Cloning & Sequencing, Recombinant Dna Technology, Rare Mutation Detection, Others)
  • 5.2.4. By Company (2022)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Real-time PCR, Digital PCR & End-point PCR Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Application
  • 6.3.2. Mexico Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Application
  • 6.3.3. Canada Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Application

7. Europe Real-time PCR, Digital PCR & End-point PCR Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Application
  • 7.3.2. Germany Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Application

8. Asia-Pacific Real-time PCR, Digital PCR & End-point PCR Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Application
  • 8.3.2. India Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Application
  • 8.3.3. South Korea Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Application
  • 8.3.4. Japan Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Application

9. South America Real-time PCR, Digital PCR & End-point PCR Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Application
  • 9.3.2. Argentina Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Application
  • 9.3.3. Colombia Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Application

10. Middle East and Africa Real-time PCR, Digital PCR & End-point PCR Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Type
  • 10.2.3. By Route Of Administration
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Application
  • 10.3.2. Saudi Arabia Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Application
  • 10.3.3. UAE Real-time PCR, Digital PCR & End-point PCR Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Product & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. Abbott Laboratories Inc
  • 15.6.2. Bio-Rad Laboratories Inc.
  • 15.6.3. Thermo Fisher Scientific, Inc.
  • 15.6.4. BIOMERIEUX SA
  • 15.6.5. Fluidigm Corporation
  • 15.6.6. F. Hoffmann-La Roche Ltd
  • 15.6.7. GE Healthcare
  • 15.6.8. Agilent Technologies, Inc.
  • 15.6.9. Qiagen NV
  • 15.6.10. Microsynth Ag

16. Strategic Recommendations